Department of Cardiovascular Medicine University of Kansas Medical Center Kansas City KS USA.
Department of Internal Medicine SUNY Upstate Medical University Syracuse NY USA.
J Am Heart Assoc. 2024 Nov 5;13(21):e036963. doi: 10.1161/JAHA.124.036963. Epub 2024 Nov 4.
End-stage kidney disease (ESKD) is commonly associated with critical limb-threatening ischemia (CLTI) and frailty. Yet there are no specific tools to predict outcomes of CLTI in ESKD, particularly those that incorporate frailty. We aimed to assess the utility of the medical record-based Hospital Frailty Risk (HFR) score in predicting outcomes of CLTI in ESKD.
We identified patients with ESKD diagnosed with CLTI from the US Renal Data System from 2015 to 2018. These patients were categorized into 3 frailty risk groups on the basis of their HFR scores: low (<5), intermediate (5-10), high-risk (>10), and on the basis of whether they underwent revascularization (endovascular revascularization [ER]/surgical revascularization [SR]) or not (no revascularization). Primary outcomes of interest included in-hospital composite of death or major amputation and in-hospital death. We included 49 454 eligible patients, with ER/SR cohort including 19.8% (n=9777). A total of 88.4% (ER/SR) and 90.0% (no revascularization) were frail on the HFR scale. We found a nonlinear association between HFR score and in-hospital adverse outcomes. In both cohorts, intermediate and high-risk HFR scores were associated with greater risk of in-hospital death (high-risk, ER/SR: odds ratio, 2.7 [95% CI, 1.6-4.8]; <0.0001; no revascularization: odds ratio, 7.8 [95% CI, 5.3-11.6]; <0.01) and composite of in-hospital major amputation or death (high-risk, ER/SR: odds ratio, 2.4 [95% CI, 1.9-3.1]; <0.0001; no revascularization: odds ratio, 1.7 [95% CI, 1.5-1.9]; <0.0001).
The HFR score can predict risk of in-hospital death and composite of death or major amputation in patients with ESKD and CLTI. Further data are needed to determine the utility of the HFR score in this population.
终末期肾病(ESKD)常伴有严重肢体缺血(CLTI)和虚弱。然而,目前还没有专门的工具来预测 ESKD 合并 CLTI 的结果,特别是那些纳入虚弱的工具。我们旨在评估基于病历的医院衰弱风险(HFR)评分在预测 ESKD 合并 CLTI 患者结果中的作用。
我们从 2015 年至 2018 年美国肾脏数据系统中确定了诊断为 CLTI 的 ESKD 患者。根据他们的 HFR 评分,这些患者被分为 3 个衰弱风险组:低(<5)、中(5-10)、高风险(>10),并根据是否进行血管重建(血管内血管重建[ER]/手术血管重建[SR])或不进行血管重建(无血管重建)进行分类。主要观察终点包括住院期间死亡或主要截肢的复合终点和住院期间死亡。我们纳入了 49454 名符合条件的患者,其中 ER/SR 队列包括 19.8%(n=9777)。在 HFR 量表上,88.4%(ER/SR)和 90.0%(无血管重建)的患者均为虚弱状态。我们发现 HFR 评分与住院不良结局之间存在非线性关系。在两个队列中,中危和高危 HFR 评分与住院期间死亡风险增加相关(高危,ER/SR:比值比,2.7[95%CI,1.6-4.8];<0.0001;无血管重建:比值比,7.8[95%CI,5.3-11.6];<0.01)和住院期间主要截肢或死亡的复合终点(高危,ER/SR:比值比,2.4[95%CI,1.9-3.1];<0.0001;无血管重建:比值比,1.7[95%CI,1.5-1.9];<0.0001)。
HFR 评分可预测 ESKD 合并 CLTI 患者住院期间死亡和死亡或主要截肢的复合终点风险。需要进一步的数据来确定 HFR 评分在该人群中的效用。